BIBLIOGRAPHIC RECORD

Future Newborns with Opioid-Induced Neonatal Abstinence Syndrome (NAS) Could Be Assessed with the Genetic Addiction Risk Severity (GARS) Test and Potentially Treated Using Precision Amino-Acid Enkephalinase Inhibition Therapy (KB220) as a Frontline Modality Instead of Potent Opioids

This record contains bibliographic metadata. Open the linked source to check the work; the record does not include its full text.

Recorded authors
Mauro Ceccanti; Kenneth Blum; Abdalla Bowirrat; Catherine A. Dennen; Eric R. Braverman; David A. Baron; Thomas McLaughlin; John Giordano; Ashim Gupta; Bernard William Downs; Debasis Bagchi; Debmalya Barh; Igor Elman; Panayotis K. Thanos; Rajendra Dhar Badgaiyan; Drew Edwards; Mark S. Gold
Source of metadata
OpenAlex
Year recorded
2022

Public identifiers and source

Open the source record

Reference

Mauro Ceccanti; Kenneth Blum; Abdalla Bowirrat; Catherine A. Dennen; Eric R. Braverman; David A. Baron; Thomas McLaughlin; John Giordano; Ashim Gupta; Bernard William Downs; Debasis Bagchi; Debmalya Barh; Igor Elman; Panayotis K. Thanos; Rajendra Dhar Badgaiyan; Drew Edwards; Mark S. Gold. (2022). Future Newborns with Opioid-Induced Neonatal Abstinence Syndrome (NAS) Could Be Assessed with the Genetic Addiction Risk Severity (GARS) Test and Potentially Treated Using Precision Amino-Acid Enkephalinase Inhibition Therapy (KB220) as a Frontline Modality Instead of Potent Opioids. https://openalex.org/W4311716388

Reference assembled from the available metadata. Check and cite the original publication before reusing a claim.

Permanent record URL: https://brain.psiconautica.org/en/documentos/d-cb6624a5c32b4fa8395c575aeed996c2/